Advertisement

Topics

Humira

22:39 EST 23rd November 2017 | BioPortfolio

Technical background:

HUMIRA is a tumor necrosis factor (TNF) blocker - further details can be viewed:

Mechanism of Action:

  • Adalimumab is a recombinant human anti-TNF monoclonal antibody
  • It complexes with soluble TNF-α and prevents its interaction with p55 and p75 surface receptors; this results in a down-regulation of macrophage & T cell function

Indications:

HUMIRA is manufactured by Abbott Laboratories and has been approved as a prescription medicine indicated for the treatment of:

  • Rheumatoid Arthritis: HUMIRA is indicated, alone or in combination with methotrexate or other non-biologic DMARDs, for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
  • Juvenile Idiopathic Arthritis: HUMIRA is indicated, alone or in combination with methotrexate, for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in pediatric patients 4 years of age and older.
  • Psoriatic Arthritis: HUMIRA is indicated, alone or in combination with non-biologic DMARDs, for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
  • Ankylosing Spondylitis: HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis.
  • Crohn's Disease: HUMIRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy, and reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.
  • Plaque Psoriasis: HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

Source: http://www.humirapro.com/
Saftety Information: http://www.humirapro.com/Utility/SafetyInformation.aspx

For further drug information refer to - http://www.bioportfolio.com/resources/drug/15156/Humira.html

Market data:

Humira is a recombinant human IgG1 monoclonal antibody (mAb) which binds to TNF-alpha and blocks interaction with p55 and p75 cell-surface receptors; this blockage reduces inflammation and stops tissue destruction. It was the first fully humanized mAb TNF inhibitor to enter the market for the treatment of RA. In 2012, pharmaceutical industry analysts estimate that Humira will be the “world’s top-selling medicine” at $9 billion in sales.

Number one selling biotechnology product in 2011 - Top 50 Biopharma Products 2011

Drug maker: AbbVie

Moderate to severe rheumatoid arthritis, moderate to severe chronic plaque psoriasis, moderate to severe Crohn’s disease; moderate to severe ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, moderate to severe polyarticular juvenile idiopathic arthritis

2012 sales: $9.265 billion

Quick Search
Advertisement
 

review and buy Humira market research data and corporate reports here